Navigation Links
Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
Date:7/13/2009

SAN MARINO, Calif.,July 13 /PRNewswire-FirstCall/ -- Viral Genetics (Pink Sheets: VRAL), a biotechnology company that develops drug compounds for HIV/AIDS, autoimmune diseases, and cancer, has retired the majority of its $3.5 million of convertible debt. The company also retired other debt and recently issued new shares.

The convertible debt originated with a March 2006 financing through the issuance of shares. This transaction originally was disclosed March 29, 2006, in a report filed on Form 8-K, with amendments filed March 2, 2007, and August 18, 2008. The company has paid all but approximately $110,000 of the principal on the $2.9 million of 10% senior secured amortizing convertible notes issued in that financing.

At that time, eleven institutional purchasers also acquired approximately $598,000 of unsecured convertible notes held by other third parties. These notes are now substantially discharged through conversion to stock, and have approximately $8,000 of remaining amounts owed under them.

All payments on both series of notes were made in shares of common stock of the company. Since Viral Genetics' February 17, 2009 Form 8-K report, the company has issued 33,751,347 common shares for the repayment of these notes.

Since March 2009, Viral Genetics has issued shares in exchange for accounts payable, advances, and private placements valued at approximately $700,000. The private placements included 33,142,800 shares and 24,200,000 warrants. Each warrant entitles the holder to purchase common stock for $0.03 per share, expiring May and June 2011. Of the shares, 19,452,800 were issued under Regulation 504 financing.

In May 2009, the company issued 5,788,945 shares and 11,577,890 warrants for advances of cash previously received in 2008 and 2009. Each of these warrants entitles the holder to acquire one share of common stock a
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website
2. New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance
3. BIO Visitors Bring Viral Preparedness to Atlanta
4. Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA
5. INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
6. Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray
7. Advanced Viral Announces Phase IIb Wound Healing Trial for AVR123
8. Researchers decode viral process that prepares cells for HIV infection
9. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
10. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
11. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 HealthTronics, Inc ... interventional radiology products and services, announced that a ... and cryoablation) versus external beam radiotherapy (EBRT) is ... American Urological Association (MAAUA) Annual Meeting in Baltimore, ... Effectiveness of Cryosurgery and External Beam Radiation as ...
(Date:9/18/2014)... 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... compounds and metabolic processes, is pleased to announce the addition ... Ms. Nola E. Masterson , a California ... effective September 17, 2014. "We,re very pleased ... board," states Andrew Dahl , President and CEO. "She ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global and Chinese Stem Cell Industry Report, ... Stem cells are undifferentiated biological cells that can differentiate ... produce more stem cells. Stem cell therapy can be ... of hematological system disease), nervous system diseases, damage or ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Leatherwood ... FM-4910 listed material, to stay competitive in the ... These high-performance materials ultimately impact product quality and ... and owner. , Established in 1980 in Lewisville, ... as many fabricators have left the business. Much ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... 15, 2006, the Supreme Court in eBay Inc. v. ... proves infringement should be granted an injunction must be ... (1) irreparable injury; (2) inadequacy of remedies at law; ... The Court rejected the Federal Circuit's approach that an ...
... encounter, we reviewed the list of the leading Big Pharma companies of ... some of the leading pharmaceuticals products and deals of 2005. , ... Product/Company Disease Area ... Lipitor (Pfizer) Cholesterol Reduction $12.9 +6% ...
... Inc., a developer of protein chip technologies, has ... the National Institutes of Health to develop a test ... ,An estimated 50 million Americans suffer from mild to ... especially for children and senior citizens. GenTel's protein chips ...
Cached Biology Technology:Supreme Court decision in eBay case could affect value of patents 2Big Pharma's continued hunger and search for new products 2Big Pharma's continued hunger and search for new products 3Big Pharma's continued hunger and search for new products 4GenTel gets federal grant to develop allergy test 2GenTel gets federal grant to develop allergy test 3
(Date:9/19/2014)... the sake of fairness per se but in order ... Frans de Waal, PhD, and Sarah Brosnan, PhD, co-authors ... is defined as a negative reaction to unequal outcomes. ... , Their conclusion comes after the co-authors reviewed more ... it is the evolution of forestalling partner dissatisfaction with ...
(Date:9/19/2014)... study shows that legume plants regulate their symbiotic ... that are transmitted through the plant structure from ... of bacteria-holding nodules in the roots. This collaborative ... Institute for Basic Biology, the Graduate University for ... Sustainable Resource Science in Japan. , Legumes, ...
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive ... Discovered by researchers at Harvard School of Medicine and ... Sciences, this is only the second "sleep node" identified ... both necessary and sufficient to produce deep sleep. , ... the study demonstrates that fully half of all of ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... number of rivers and lakes are being invaded by exotic ... Such species represent a threat to native species, as they ... the case of the mudsnail Potamopyrgus antipodarum ... and has spread throughout rivers, lakes or streams in Europe, ...
... found that silicone foul release coatings may be an important ... water and hydropower infrastructure. Allen D. Skaja, Ph.D., PCS, of ... metal alloys over three years at Parker Dam on the ... to reduce the rate of mussel settlement, and any attached ...
... Calif. ( www.ucr.edu ) Research by Nosang ... Riverside, Bourns College of Engineering, has enabled a ... that can detect small quantities of harmful airborne ... Economy Corporation company, has completed the prototype which ...
Cached Biology News:Survival without water: A key trait of an aquatic invader to spread 2'Electronic nose' prototype developed 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: